Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
NCT01208896Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Feb 2011
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in follicular lymphoma (FL), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Overall Survival at 2 years. Started Feb 2011; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01208896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01208896.